Shengyuan Life Technology and Xingyao Kunze Biopharmaceuticals, both based in Anji county, Huzhou, East China's Zhejiang province, recently presented their research findings at the 76th Annual Meeting of the American Association for the Study of Liver Diseases in Washington, D.C.
The AASLD Annual Meeting is a leading international conference in liver disease research, promoting advancements in liver health and patient management.
Shengyuan Life Technology specializes in dual humanized mouse models, useful for hepatitis B virus research and simulating human immune diseases and cancer immunotherapy. These models are valuable for new drug development in cancer and tumors.
Xingyao Kunze focuses on RNA interference, antibodies, fusion proteins, and gene editing, addressing challenges in the treatment of liver diseases such as hepatitis B, non-alcoholic fatty liver disease, and cirrhosis.
Shengyuan's chief expert Li Jun, a professor from the First Affiliated Hospital of Zhejiang University School of Medicine, presents research reports at the meeting. [Photo/Tide News]
At the conference, Shengyuan's chief expert Li Jun, a professor from the First Affiliated Hospital of Zhejiang University School of Medicine, presented five research reports, including work on functional bile duct organoids, which attracted significant attention.
Xingyao Kunze showcased clinical trial results of two hepatitis B treatments developed using a dual-technology platform. Trials showed a 90 percent success rate in achieving hepatitis B surface antigen clearance within 24 weeks of combined therapy, marking a major step toward a functional cure.
"Our mission is to advance Phase III clinical trials and establish production capabilities," said He Yan, vice-president of Xingyao Kunze, as she announced plans for a production base in Anji.
浙公网安备33010502011796号
